The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday.

Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over ...

This follows the final approval from the US FDA for its abbreviated new drug application (ANDA). Shares of Lupin Ltd ended at ...

Lupin announced that it has launched Rivaroxaban tablets USP, 2.5 mg, in the US market following final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug ...

Mumbai: Global pharma major Lupin Limited has announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the ...

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA.

Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto.

Global pharma major Lupin Limited (Lupin) announced that it has launched rivaroxaban tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the US FDA.

The approval is only for the 2.5mg tablet. Xarelto is also available in 10mg, 15mg, and 20mg tablets, as well as an oral suspension (1mg/mL), to treat various conditions.